Inebilizumab + VIB4920 + Inebilzumab+VIB4920
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Conditions
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Trial Timeline
Dec 27, 2019 → Apr 1, 2022
NCT ID
NCT04174677About Inebilizumab + VIB4920 + Inebilzumab+VIB4920
Inebilizumab + VIB4920 + Inebilzumab+VIB4920 is a phase 2 stage product being developed by Amgen for Highly Sensitized Patients on Waiting List for Kidney Transplantation. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04174677. Target conditions include Highly Sensitized Patients on Waiting List for Kidney Transplantation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04174677 | Phase 2 | Withdrawn |
Competing Products
5 competing products in Highly Sensitized Patients on Waiting List for Kidney Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| everolimus + low-dose tacrolimus | Novartis | Phase 2 | 52 |
| carfilzomib + belatacept | Bristol Myers Squibb | Phase 1/2 | 40 |
| daratumumab + belatacept | Bristol Myers Squibb | Phase 1/2 | 40 |
| UCB0942 | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |